… Maintenance therapy with erlotinib for patients with NSCLC is well tolerated and significantly
prolongs PFS compared with placebo. First-line maintenance with erlotinib could be …

… This study investigated maintenance gemcitabine or erlotinib versus observation, following
induction chemotherapy. Only the data of erlotinib and observation arms were extracted for …

… similar and significant benefits with maintenance erlotinib, compared with placebo, for both
the SD and CR/PR groups (Figure 1A and 1B). The HR for erlotinib benefit was 0.68 in the …

… were randomized to receive blinded maintenance erlotinib 150 mg/day (‘early erlotinib’) or
… open-label erlotinib (‘late erlotinib’); patients who progressed on erlotinib received approved …

… For drugs such as erlotinib and … of maintenance therapy is being evaluated [11–13]. The
present manuscript concerns the FDA's recent approval of erlotinib as first-line maintenance …

… and the good toxicity profile of erlotinib make it a … of erlotinib therapy in advanced NSCLC.
It summarizes current data and perspectives of erlotinib in upfront treatment and maintenance …

… Based on this study, the EMA and FDA both approved erlotinib in 2010 as a maintenance …
for the effect of maintenance treatment is that the ‘switch maintenance’ treatment may simply …

… use as maintenance treatment in … erlotinib as monotherapy for maintenance treatment in
patients with NSCLC. Medical literature on the use of erlotinib as monotherapy for maintenance …

… confirm the benefit of maintenance erlotinib in patients with advanced NSCLC who had not
progressed after four cycles of induction (platinum-based) chemotherapy. Erlotinib leads to a …

… demonstrated that maintenance therapy with erlotinib after the … (OS) of non-small cell lung
cancer (NSCLC) patients with … III trial comparing erlotinib maintenance to erlotinib second-…